Investment Q&A

Q: I have owned HCG since 2000.This is a stock I thought I may never sell, but due to circumstances I have considered selling especially after your advise to get out. At what price would you sell as the stock can go up or down 15% in a day? I do not think putting a market price would by wise. I was considering selling at $8.00 per share but the next day the shares were down to about $6.75. Today they are trading at $7.75.

Q: David Taylor was interviewed in the Globe and Mail today. He feels there is value in HCG. His optimism rests on the book value of the company, which he estimates is between $15 and $28 a share. Do you feel this is a reasonable estimate of book value? If so could there be a significant opportunity for brave and patient investors?

Q: Would you recommend investing in this preferred at this time (given the drop in its price recently), and would you consider the preferred as a safer investment vs investing in the common shares. The reset is Canada 5 year bond yield + 4.78% (September 30, 2019). I am not sure, but are there any more Canada bonds to be issued going forward? If not how will the rate be set in the absence of further Canada bonds being issued..

Q: Good Day,

I slowly building a US portfolio and already own (DIS, MKSI, and JPM.) What other names would you suggest for the remaining sectors? Mostly looking for long terms growth.

Thanks
Marco

Q: I've been interested in NXO lately due to the market activity so I did a bit of research on the technology itself. The theory of flat lenses and the proof of concept that it works was discovered by Federico Capasso and his team at Harvard University. When their research paper was first published, Federico Capasso was contacted by one of the world's largest smartphone manufactures (which means they are now working on it). Since then many of the research team members have been picked off by various universities and companies world wide to develop it's potential further.
The point is (NXO) Nexoptic did not invent the technology of their prototype lens system.
So investors beware that NXO really has nothing proprietary, nor do they have the size and scale of potential competitors. The idea that an iPhone will someday have Nexoptic lenses is probably a bit of a stretch. The best outcome I see is that their telescope patent (if approved) is sold to a larger manufacturer, which is not going to make the average investor any money over the next 5 years.
I hope I'm wrong and wish them luck!

Shane

Q: Over the last 2 years, I lost quite a lot of money investing in a promotional companies, or, companies with growth profiles too good to be true. On the other hand, I always made money investing in a company that meets all the following criterias: (1) boring (2) sells products I use (3) existed for 5 years (4) pays a dividend under 4%. Jean-Coutu meets passes this test so I'm considering it my father's portfolio. Is there something *not* to like about it? How about the latest news on the government meddling with drug generics pricing. This this take a positive turn? Thank you!

Q: Regarding VSN (Veresen) being bought by Pembina (PPL), some are suggesting this might put Enbridge in an untenable position (50% of Alliance!), and they will/should/could make a competing bid, particularly as the premium for VSN is still below what it was trading for a year or two back (as high as $19.40 in 2015, although they have sold assets since). Do you see this as a likely possibility? Is that what is causing VSN to trade below its takeout price?

Q: Please comment on AW.UN release today? Thx

Q: Hi 5i team,
Can I have your comments on the recent results published by Colliers intl? Also is it a buy, hold, sell at currel level. Thanks!

Q: Would you consider SHOP a buy at these levels.

Thank You
Craig

Q: Hello, 5i Team,

This is a question from a neophyte investor.

In a recent press release BUS announced the acceleration of A & B Convertible Debentures. To quote: "The Debentures will result in the issuance of up to 2,235,294 Common Shares at an issue price of $0.68 per share."

Can you tell me a) why a Company might accelerate the issuance of debentures and, b) just as importantly, how such an issuance, at that price, would impact upon current shareholders and the value of their shares.

Thank you

Q: Thoughts on Span-America Medical System acquisition announced yesterday?

Q: I understand that you guys don't like this space. I'm warming up to it and would like to take advantage of HCG's collateral damage. Pls rank the above and describe how they fund their deposits. Thanks!

Q: This little upstart fintech released earnings May 1st. Showed huge revenue growth and cashflow for Q1. Risky venture stock but growth potential looks good. Appreciate your thoughts on this one.

Q: Can you please give me your thoughts on Imperva (IMPV)?

Q: What do you think of Royalty North? They just signed a few deals. Still no dividend, but do you think it is coming? Are they issuing too many shares and warrants to make this worthwhile holding?

Q: What do you think is an appropriate weighting in the energy sector at this time? Please also highlight a couple names you feel are good buying opportunities.

Q: Hi Team,

Just wondering your thoughts on the company today. I read comments from a few years ago and it looked like you liked the company at that time. Would you be a buyer? If so, short or long term.

Thank you

Q: hi Peter, your opinion please on K and GILD.
ARE THESE WORTH NEW MONEY.THANKS.

Q: This company trades on the NYSE but is headquartered in Canada. It has been a disappointment for shareholders, especially after it shifted its business model a couple of years ago.

Do you have any insight into the soundness of its business model or opinion on its prospects?